Brief: Solid Biosciences Says Ends Q1 With About $185.5 Mln In Cash
May 11 (Reuters) - Solid Biosciences Inc SLDB.O :
* SOLID BIOSCIENCES INC SAYS ENDS Q1 WITH ABOUT $185.5
MILLION IN
CASH AND INVESTMENTS; ANTICIPATED CASH RUNWAY INTO 2025
* SOLID BIOSCIENCES INC SAYS NO COLLABORATION REVENUES FOR
Q1 OF
2023
* SOLID BIOSCIENCES INC SAYS NET LOSS FOR Q1 OF 2023 WAS
$30.1
MILLION
Source text for Eikon: ID:nGNX6Lq190
Further company coverage: SLDB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Solid Biosciences
See all newsMarketing Agreement To Advance Gene Therapy Delivery And Analytics
Solid Biosciences Q1 net loss widens on higher R&D costs
Solid Biosciences Q4 net loss widens on higher R&D costs
NASDAQ RESUMED AT 01:58 PM
Brief: Solid Biosciences Provides Interim Positive Clinical Update On Phase 1/2 Inspire Duchenne Trial